This study is in progress, not accepting new patients
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
Summary
- Eligibility
- for people ages 10-18 (full criteria)
- Location
- at UCSD
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Biogen
- ID
- NCT03958877
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 142 study participants
- Last Updated